Fig. 7: Targeting PDGFR-B in vivo (B-C) and in vitro (D-G).
A Expression level of PDGFR-B by cytofluorimetric analysis. Profiles: gray, secondary antibody; blue, MamBo89HER2stable cell line; black, MamBo43HER2labile cell line; green, MamBo38HER2loss cell line; red, trastuzumab-treated MamBo43HER2labile cell line (MamBo43HER2labile TRT). B Effect of sunitinib on MamBo43HER2labile tumor growth. Sunitinib significantly reduced tumor growth from the 37th day after cell injection onward, p < 0.05, at least, by unpaired t test with Welch’s correction. C Effect of sunitinib on MamBo38HER2loss tumor growth. Sunitinib significantly reduced tumor growth from the 11th day after cell injection onward, p < 0.05, at least, by unpaired t test with Welch’s correction. In B, C untreated mice (black square, MamBo43HER2labile or green square, MamBo38HER2loss) or 60 mg/Kg sunitinib-treated mice (orange circle). Data shown are the mean and SEM from 4–5 mice per group. D–G Effect of sunitinib (5 μM) on MamBo38HER2loss. D Mammosphere formation assay. Data shown are the mean and SEM, n = 2–4 for each group; p < 0.001, sunitinib vs untreated or vehicle by Student’s t-test. E Wound-healing assay. Data shown are the mean and SEM, n = 6–8 for each sunitinib-treated group. p < 0.001, vs untreated or vehicle by Student’s t-test. F IL6 production detected by ELISA. G Western blotting analysis for STAT3 and pSTAT3 on cells treated with sunitinib.
